Sesen Bio, Inc. (SESN)
| Market Cap | 210.75M |
| Revenue (ttm) | 11.24M |
| Net Income (ttm) | -48.10M |
| Shares Out | 117.89M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $1.62 |
| Previous Close | $1.66 |
| Change ($) | -0.04 |
| Change (%) | -2.41% |
| Day's Open | 1.65 |
| Day's Range | 1.60 - 1.69 |
| Day's Volume | 1,349,164 |
| 52-Week Range | 0.39 - 1.77 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today repo...
Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...
Sesen Bio (SESN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma ...
Sesen Bio, Inc. (SESN) CEO Thomas Cannell On Q3 2020 Results - Earnings Call Transcript
Sesen Bio, Inc.'s (SESN) CEO Thomas Cannell on Q3 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today repo...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today annou...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...
Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today repo...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with c...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu P...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...
Sesen Bio's (SESN) CEO Thomas Cannell on Q4 2019 Results - Earnings Call Transcript
Sesen Bio: Growing A Position Through The Rolling BLA Summary
Sesen Bio With High Probability FDA Approval Upcoming
Sesen Bio's (SESN) CEO Thomas Cannell on Q3 2019 Results - Earnings Call Transcript
ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.
The company reported a positive data update from the Phase 3 VISTA trial for BCG refractory high-grade NMIBC patients.
Sesen plunged 35% after announcing a stock offering.
Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.
The stock more than doubled within the past two months.
Sesen Bio (SESN) needs investors to pay close attention to the stock based on moves in the options market lately.
The company meets with the FDA on May 20 to discuss manufacturing aspects.
Sesen Bio, Inc. (SESN) CEO Thomas Cannell on Q1 2019 Results - Earnings Call Transcript
An upcoming data readout for the phase 3 VISTA trial using Vicinium in NMIBC patients who don't respond to BCG therapy is expected by May 13, 2019.
On March 4, Sesen Bio's President and CEO Dr. Thomas Cannell held a conference call, primarily to update the status and progress of Vicinium.
About SESN
Sesen Bio, a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of EpCAM-positive solid tumors. It also d... [Read more...]
| Industry Biotechnology | IPO Date Feb 6, 2014 |
| CEO Thomas Cannell | Employees 25 |
| Stock Exchange NASDAQ | Ticker Symbol SESN |
Analyst Forecasts
According to 3 analysts, the average rating for Sesen Bio stock is "Strong Buy." The 12-month stock price forecast is 3.42, which is an increase of 111.11% from the latest price.